{
    "organizations": [],
    "uuid": "ec107883c3909b2df80e00b51d98c1cd0a0e8264",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-avexis-announces-first-patient-dos/brief-avexis-announces-first-patient-dosed-in-phase-3-trial-of-avxs-101-in-pre-symptomaticsma-types-1-2-and-3-idUSASC09XAV",
    "ord_in_thread": 0,
    "title": "BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - AveXis Inc:\n* AVEXIS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 TRIAL OF AVXS-101 IN PRE-SYMPTOMATIC SMA TYPES 1, 2 AND 3 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T20:10:00.000+03:00",
    "crawled": "2018-04-26T21:02:50.027+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "avexis",
        "inc",
        "avexis",
        "announces",
        "first",
        "patient",
        "dosed",
        "phase",
        "trial",
        "sma",
        "type",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}